

Answering reviewers

June 12, 2016

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 26218

Manuscript Type: TOPIC HIGHLIGHT

Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma

Chung-Tzu Hsueh, Julie H. Selim, James Y. Tsai, Chung-Tsen Hsueh

*Reviewed by 03590776*

Comments To Authors

This review is very informative and detailed with a consistent number of references. Just a little notice. I suggest to the authors to insert a comment about this recent publication that I find during this revision in the conclusions about the paragraph of Nabpaclitaxel plus gemcitabine treatment: Nabpaclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Pernot S, Bachet JB, Portal A, Taieb J. Br J Cancer. 2016 Apr 28. doi: 10.1038/bjc.2016.70.

Our answer:

Thank you for the comment and suggestion. We have added one sentence at the end of first paragraph on page 19, citing the reference from “Pernot S, Bachet JB, Portal A, Taieb J. Br J Cancer. 2016 Apr 28. doi: 10.1038/bjc.2016.70” as highlighted in yellow: “Phase II study with nab-paclitaxel/gemcitabine as 2<sup>nd</sup>-line treatment showed promising activity in patients with rapid progression (PFS less than 248 days) from FOFIRINOX as first-line treatment <sup>[59]</sup>”.

Reviewed by 00077376

Comments To Authors

The authors reviewed the mechanism of action and clinical studies of the 2 U.S. FDA approved nanomedicines in pancreatic adenocarcinoma. This is well written review.

Our answer:

Thank you for the comment. No revision is recommended by this reviewer.